Thromboembolic disorders:
Indications for KENGREAL:
As adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Adult Dosage:
Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.
Children Dosage:
Not established.
KENGREAL Contraindications:
Significant active bleeding.
KENGREAL Warnings/Precautions:
Increased risk of bleeding. Discontinue 1hr prior to labor, delivery or neuraxial blockade. Pregnancy. Nursing mothers.
KENGREAL Classification:
P2Y12 platelet inhibitor (ATP analog).
KENGREAL Interactions:
Administer clopidogrel or prasugrel after infusion is discontinued.
Adverse Reactions:
Bleeding, renal impairment, dyspnea, hypersensitivity reactions.
Generic Drug Availability:
NO
How Supplied:
Single-use vial (10mL)—1, 10
